Vyas Charmee, Dalmacion Denise, Almeligy Abdalrahman, Juan Rojas, Pernia-Cuberos Julio D, Obaid Asef, Heis Farah, Patel Shailee, Eng Margaret H, Patton Chandler D, Lee Andrew
Internal Medicine, Monmouth Medical Center, Long Branch, USA.
Internal Medicine, Monmouth Medical, East Orange, USA.
Cureus. 2021 Dec 23;13(12):e20651. doi: 10.7759/cureus.20651. eCollection 2021 Dec.
Multisystem inflammatory syndrome (MIS) is a rare entity that usually presents with a constellation of symptoms such as fever, hypotension, gastrointestinal symptoms, cardiac dysfunction, or dermatological involvement, representing an inflammatory state. During the ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, several cases of multisystem inflammatory syndrome in children (MIS-C) have been described in the literature. The Centers for Disease Control and Prevention (CDC) has acknowledged the increasing incidence of the same entity in adults, referred to as multisystem inflammatory syndrome in adults (MIS-A). This case series describes four patients who presented to the Monmouth Medical Center in New Jersey with symptoms suggestive of MIS-A associated with SARS-CoV-2 infection and their clinical outcomes. All patients were within the age group of 20-40 years with no underlying medical condition. The period between SARS-CoV-2 infection and the development of MIS-A varied from 10 days through a month. Presentations ranged from a mild flu-like illness to shock requiring vasopressors. A positive SARS-CoV-2 antibody test was essential for the diagnosis. Inflammatory markers, such as ferritin, D-dimer, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and interleukin-6 (IL-6), were elevated on admission. The Use of immunomodulatory agents, namely steroids and intravenous immunoglobulin (IVIG), resulted in positive clinical outcomes. Inflammatory markers and imaging on admission did not appear to predict the disease course. A positive SARS-CoV-2 polymerase chain reaction (PCR) did not appear to influence the response to treatment. Given the high probability of MIS-A with negative viral testing, the use of both antibody and viral testing with the addition of inflammatory markers may be essential to diagnose this SARS-CoV-2-associated condition.
多系统炎症综合征(MIS)是一种罕见的病症,通常表现为一系列症状,如发热、低血压、胃肠道症状、心脏功能障碍或皮肤受累,代表一种炎症状态。在当前严重急性呼吸综合征冠状病毒2(SARS-CoV-2)大流行期间,文献中已描述了几例儿童多系统炎症综合征(MIS-C)。美国疾病控制与预防中心(CDC)已认识到该病症在成人中的发病率不断上升,即成人多系统炎症综合征(MIS-A)。本病例系列描述了四名前往新泽西州蒙茅斯医疗中心就诊的患者,他们的症状提示与SARS-CoV-2感染相关的MIS-A及其临床结局。所有患者年龄在20至40岁之间,无基础疾病。SARS-CoV-2感染至MIS-A发病的时间间隔从10天到1个月不等。临床表现从轻度流感样疾病到需要血管升压药的休克。SARS-CoV-2抗体检测呈阳性对诊断至关重要。入院时,铁蛋白、D-二聚体、C反应蛋白(CRP)、红细胞沉降率(ESR)和白细胞介素-6(IL-6)等炎症标志物升高。使用免疫调节药物,即类固醇和静脉注射免疫球蛋白(IVIG),产生了积极的临床结果。入院时的炎症标志物和影像学检查似乎无法预测疾病进程。SARS-CoV-2聚合酶链反应(PCR)呈阳性似乎不影响治疗反应。鉴于病毒检测阴性时MIS-A的可能性较高,同时使用抗体和病毒检测并加上炎症标志物可能对诊断这种与SARS-CoV-2相关的病症至关重要。